Portal de Periódicos da CAPES

Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study

2024; Wiley; Volume: 26; Issue: 11 Linguagem: Inglês

10.1111/dom.15898

1463-1326

Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tsunekazu Oikawa, Toshifumi Tada, Kentaro Matsuura, Toru Ishikawa, Hiroshi Abe, Keizo Kato, Asahiro Morishita, Joji Tani, Tomomi Okubo, Mototsugu Nagao, Masato Iwabu, Katsuhiko Iwakiri,

Diet, Metabolism, and Disease

To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).